Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABS-201 SAD/MAD in healthy volunteers and androgenetic alopecia
NCT07317544Phase 2Recruiting
- Sponsor
- Absci
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ABSK201 in androgenetic alopecia (AGA), sponsored by Absci. Started Dec 2025; status: recruiting.
02
Drugs
ABSK201
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07317544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317544.